More than 500 clinical AI algorithms have now been cleared by the FDA, with the majority just in the past couple years.

There are now more than 520 FDA-cleared AI algorithms and the majority are for radiology and cardiology, raising the question of who is liable if the AI gets something wrong.

Post-operative atrial fibrillation was once viewed as a fairly insignificant issue, but more recent research suggests it can increase a patient’s risk of multiple adverse events. 

The human author reviewing the article wrote about the benefits and inherent risks of utilizing AI in a medical publication setting, concluding that, overall, it could be “a powerful tool” used in the future of medical publishing—when used with caution.

Brent Savoie, MD, JD, vice chair for radiology informatics, section chief of cardiovascular imaging, Vanderbilt University, explains who will get sued when there is a misdiagnosis due to artificial intelligence (AI).

Clarius Mobile Health of Vancouver, B.C., has won FDA approval to market an AI model that works with the company’s handheld point-of-care ultrasound devices to identify and measure tendons of the foot, ankle and knee.

The model augmented and significantly improved diagnostic performance for abdominal subspecialists as well as residents—a result researchers say has major clinical implications.

Radiomics features could be especially useful for determining TSS in scenarios where clinical data is lacking or unreliable, such as when patients have altered mental status.